ArticleCancer chemotherapy and pharmacology2026
Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSunitinib, a multitargeted tyrosine kinase inhibitor, is used in advanced clear cell renal cell carcinoma (ccRCC). Corrected QT interval (QTc) prolongation is a recognized cardiovascular toxicity of this therapy.
aimTo evaluate the incidence, timing, and severity of QTc prolongation in real-world advanced ccRCC patients treated with first-line sunitinib, compare Bazett’s and Fridericia’s correction formulas, and identify risk factors. MATERIALS AND
methodsThis retrospective single-center cohort study included 67 patients between January 2019 and June 2022. QTc was calculated manually using Bazett’s and Fridericia’s formulas and graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The incidence, timing, and severity of QTc prolongation were assessed based on the highest recorded QTc value. Statistical analyses compared QTc values between formulas and evaluated potential clinical predictors of QTc prolongation.
resultsThe median treatment duration was 1.4 years (IQR 0.72–2.99). QTc prolongation ≥ 450ms occurred in 44.8% of patients (Bazett) and 34.3% (Fridericia) and ≥ 500ms in 7 and 6 patients, respectively. The median onset of QTc ≥ 450ms was cycle 7.9 (Bazett) and 10.4 (Fridericia). Bazett’s values were significantly higher across most treatment cycles (p < 0.05). Older age, thyroid dysfunction, smoking history, hypertension and soft-tissue metastases were associated with increased risk of QTc prolongation.
conclusionsQTc prolongation was frequent and occurred both early and later during therapy. Fridericia’s formula provided more accurate and stable values and should be preferred for monitoring. Repeated ECG measurements and close cardio-oncology collaboration are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.